알테오젠 196170
Close as of Oct 12
₩231,500 -3.94%
Low ₩194,671 52-week range High ₩437,818
Mar 31 ~ Oct 12
₩231,500 -11.90%
1M 3M 6M
Low ₩206,213 High ₩348,000
Strong outflow index -₩3.2B Net flow, Outflow
Market flow rank Outflow #18 of 52
Sector flow rank #12 of 13 Today's overlaps
Loan balance building + outflow index
Multi-day trend, Persistent outflow
Cumulative flow -₩11.1B
outflow 3d streak Estimated from public price, change and volume. Not actual investor net buying.
Lending balance Building 1D +5.39% 5D +12.29%
New 478,606 sh, Returned 232,667 sh
Shares borrowed through securities lending that have not yet been returned. Borrowed shares are often sold afterwards, so the balance is used as a reference for pending sell pressure.
As of 2026-10-12, FSC stock lending data
1 to check first, 1 improvements checked through Oct 14
This only counts facts confirmed in filings. It does not look at whether the price is cheap or expensive, and it is not a reason to buy or sell on its own.
Company research researched Sep 18 The KRW 253.2bn plant the board approved on August 21 is 1.8 times first-half revenue of KRW 140.5bn and 55.7% of equity at the end of 2025.
Alteogen's consolidated first-half 2026 revenue was KRW 140.5bn, with operating profit of KRW 73.5bn and net profit of KRW 101.3bn, up 37%, 21% and 108% from a year earlier. The company said the result reflects upfront payments and milestones from the ALT-B4 license agreements signed in the first quarter with Biogen and with GSK subsidiary Tesaro. On August 21 the board approved KRW 253.2bn for a new plant in the Dungok district of Daejeon, which the filing puts at 55.7% of equity. The first money tied to actual product sales was the USD 25m sales milestone disclosed on August 31.
First-half revenue KRW 140.5bn
First-half operating profit KRW 73.5bn
First-half net profit KRW 101.3bn
New plant investment KRW 253.2bn
Investment as share of equity 55.7%
First sales milestone USD 25m Read the full research Of 13 covered Healthcare stocks in Korean, 12 fell; the average change was -3.35%. ALTEOGEN moved in the same direction at -3.94%. Estimated sector flow was outflow.
Variables to watch Drug approvals and trial results, Drug pricing policy, US interest rates, USD/KRW
Risks to check -59% below the high, the downtrend may continue, Clinical trial failure, Drug pricing pressure
Same-sector channels
Posts are members' opinions. Investment decisions and their consequences are your own.
Data: KRX daily bars, InverseOne quote snapshots, public news feeds, DART filings, InverseOne company research. Not a call to buy or sell.
